Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies.

Millar B, de Gaetano M

Open source

DOI
10.3389/fphar.2023.1125858
Published
2023
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2023.1125858,
  title = {Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies.},
  author = {Millar B and de Gaetano M},
  year = {2023},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2023.1125858},
  url = {https://doi.org/10.3389/fphar.2023.1125858}
}

RIS

TY  - JOUR
TI  - Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies.
AU  - Millar B
AU  - de Gaetano M
PY  - 2023
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2023.1125858
UR  - https://doi.org/10.3389/fphar.2023.1125858
ER  - 

APA

B, M., & M, D. G. (2023). Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2023.1125858

Source records